Form 8-K - Current report:
SEC Accession No. 0001178913-25-001909
Filing Date
2025-05-21
Accepted
2025-05-21 09:20:16
Documents
15
Period of Report
2025-05-21
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2533232.htm   iXBRL 8-K 50437
2 EXHIBIT 99.1 exhibit_99-1.htm EX-99.1 12934
7 image0.jpg GRAPHIC 19432
  Complete submission text file 0001178913-25-001909.txt   269197

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250521.xsd EX-101.SCH 4740
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250521_def.xml EX-101.DEF 18263
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250521_lab.xml EX-101.LAB 27748
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250521_pre.xml EX-101.PRE 20505
18 EXTRACTED XBRL INSTANCE DOCUMENT zk2533232_htm.xml XML 6552
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 25971066
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)